At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
ATI-450 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
In Brief
A Phase 2 clinical trial evaluating ATI-450 and Placebo oral tablet for Hidradenitis Suppurativa. Completed, enrolled 95 participants across 20 sites.
Detailed Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionDec 2022
Study CompletionJan 2023
TodayJul 2026
First PostedJan 31, 2022
Enrollment StartDec 29, 2021
Primary CompletionDec 23, 2022
Study CompletionJan 24, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.4 years ago
Interventions
ATI-450drug
Oral, small molecule MK2 inhibitor
Placebo oral tabletdrug
Placebo tablet manufactured to match ATI-450 in appearance